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that has been implemented in Turkey since December 2012. Total volume of PHI in 
Turkey is expected to expand more as the scope of the supplementary health insur-
ance implementation increases. There exists a diminishing trend of OOP expenses 
across all three countries however this is again relatively much lower for Turkey. 
Since 2003, Turkey has been implementing a Health Transformation Program where 
PHI is expected to play a crucial role to reduce OOP health expenditure. Despite this 
ten-year program, OOP spending has decreased slightly (11%) when compared to 
South Africa where there is a threefold decrease. ConClusions: Turkey has still 
room to improve its private insurance system along with its public system to reduce 
OOP payments. South Africa with private dominant health insurance system and 
lower OOP spending is trying to transfer its resources towards a national health 
insurance system. United States stands as a stabilized private dominant health 
insurance model which significantly differs from Turkey and South Africa.
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objeCtives: The need to use real-world data to support Health Care decision was 
the main driver for the Italian Inter-University Consortium (CINECA) to set-up a 
population-based patient centric database (ARNO Observatory) which integrates 
big administrative data from National/ Regional Information Systems to monitor 
health economics, patient’s outcomes and measure health performance in the 
real world. Methods: On a population of almost 12 million, since 1987, ARNO 
Observatory routinely collects and integrates NHS administrative data for each 
single patient with high quality and complete information. ARNO provides com-
prehensive data referred to patient as: demographics, outpatient drug prescrip-
tions, inpatient hospital discharges, imaging and lab tests prescriptions. From 
ARNO Observatory we carried out analyses of population or on specific cohorts 
to evaluate prevalence of chronic disease, co-morbidities and cost of total burden 
of illness. Results: From a cohort of 2,5 million of ARNO population, one third 
subjects has at least one chronic disease during 2012 and this proportion rises with 
ages (84% in elderly over 80 years). The most common chronic disease is hyper-
tension (23%), followed by COPD/asthma (13%), dyslipidemia (10%) and diabetes 
(6,3%). Integration of different data flows led to the evaluation of cost of illness 
which varies from 2.000€ for hypertension or 2.800€ for diabetes to 12.000€ for Acute 
Coronary Syndrome. Most part of this cost is due to hospitalization (49% vs 40% for 
drugs and 12% for diagnostic examination and lab tests). Cost of illness is strictly 
correlated to age and presence of co-morbidities, actually a considerable number 
of patients has more than one disease (17%), in elderly this percentage rises up 
to 50%. ConClusions: A big data infrastructure is very important to integrate 
administrative and clinical data for real world analyses and it is a valid instrument 
to support clinical governance and clinical research decision making.
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objeCtives: Estimate the financial savings associated with participation in a 
transitional case management (TCM) program offered by Optum. Nurses managed 
cases via telephone and face-to-face interventions following member’s inpatient 
admission. The program was designed to improve care and help save money by 
better managing post-discharge care of the participants. Methods: Propensity-
score-weighted difference-in-difference multiple regression analyses were used to 
estimate savings in total health care expenditures associated with active engage-
ment in the CAD program. Factors associated with the program participation and 
savings were also found via logistic regression. The study included cohorts of 80,032 
participants and 29,054 non-participants who qualified for the program between 
July 2011 and December 2012. Pre- and post-program engagement periods extended 
for up to 12 months before and after the dates members qualified for the program. 
Regression models controlled for age, gender, and health conditions along with 
inferred demographic characteristics such as minority status, education, income, 
and the supply of health care services in members’ zip code of residence. Results: 
The regression-adjusted average cost trend was $231 lower per member per month 
for program participants. About 42.4% of the participants were managed in a way 
that their cost savings exceeded the costs of providing the program. Factors asso-
ciated with engagement were not always associated with program savings. For 
example, lower income and lower supply of health care service areas were associ-
ated with lower participation rates but higher saving. On the other hand, those with 
higher risk scores and in higher age group were more likely to engage and also more 
likely to be managed in a way that lead to savings as well. ConClusions: The TCM 
program helped to generate savings. Analyses of participation and savings allowed 
program providers to understand the pockets of program success and streamline 
future efforts to improve the program.
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objeCtives: Taiwan’s National Health Insurance, established in 1995, has offered 
every citizen nearly equal financial access to comprehensive health services and 
provides all citizens with financial risk protection from large medical expenses. 
Existing data reported that purchasing private life and annuity insurances is popular 
in Taiwan, with an average of 2.3 contracts per person and 18% of GDP invested in 
products. The average prices per physical unit and price changes after the policy 
varied significantly by manufacturer type: 1.8 EGP (0.26 $USD) for drugs produced by 
state-owned companies increased by 238%, 2.3 EGP for domestic-private company 
products increased by 10%, 13 EGP for multinationals products decreased by 6%, 
and 41 EGP for imported products increased by 13%. ConClusions: Switching 
to a referent price policy for pharmaceuticals resulted in considerable percentage 
increase, on average, for products where a price change occurred. However, the 
nominal effect was attenuated because the biggest proportional changes occurred 
on the lowest cost drugs.
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objeCtives: To understand hospitalization costs, costs covered by insurance and 
disease distribution among urban inpatients with basic health insurance (BHI) 
in China between 2010 and 2011, providing data evidence for the government 
to improve BHI policies and drug regulation system in the further. Methods: A 
nationwide, cross-sectional sampling of urban inpatients with BHI was conducted 
in mainland China. A retrospective analysis was adopted and all results were 
extrapolated to the whole country according to the population, economics and 
other factors in the inpatients’ cities. The statistics analysis software was SQL Server 
2003. Results: There were 38.2 million hospitalization cases after extrapolating 
(sample= 375822) in 2011, with an increase of 21.42% than that of the previous year. 
Three-class hospitals received more hospitalization cases (43.56% of the total) in 
2011 than the previous year (40.10% of the total). Average hospitalization cost per 
visit in 2011 was 8210 RMB, an increase of 1.90% from the previous year. Remarkably, 
medication expenses accounted for about 49%, which was approximately equal to 
the previous year. The expenses covered by BHI accounted for 68.39% for each visit, 
which was higher than that of the previous year. Cerebrovascular disease had the 
most hospitalization cases (9.11% of the total), followed by cancer, ischemic heart 
disease, Hypertension and diabetes. The total hospitalization cost of cancer (37.8 bil-
lion RMB) was the highest, followed by cerebrovascular disease (32.8 billion RMB) and 
ischemic heart disease (25.7 billion RMB). ConClusions: The average hospitaliza-
tion costs per visit and total hospitalization costs all increased. And rational drug 
use should be still paid more attention since the drug costs percentage was steadily 
high. Helping inpatients select proper hospitals to see doctors and strengthening the 
administration of diseases cost highly will be helpful for reducing the medical costs.
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objeCtives: Analysis of large datasets such as claims and health care utilization 
databases has become a routine way that drug, device and diagnostic manufacturers 
understand current treatment pathways and project market potential for develop-
ment products. The time, resources, and costs associated with these data analyses 
can be a barrier for small- to mid-size companies operating under the pressure of 
lean development processes. We sought to analyze the current published litera-
ture on claims analyses in four therapeutic areas (cardiovascular, ophthalmology, 
oncology, and women’s health) to better understand the size of companies engag-
ing in this type of research. Methods: A literature review of published articles 
from January 1, 2000 – December 31, 2013 was conducted to better understand the 
analyses of large datasets being conducted by company size. The data were then 
abstracted to obtain the following data: therapeutic area, funding support for data 
analysis, company size, large dataset utilized, approximate cost of obtaining data, 
approximate cost of analyzing data, approximate US patient population for drug/
device/diagnostic under development. Results: Analyses of large datasets were 
just as likely to be conducted by government and academic institutions as private 
sector organizations (research firms and manufacturers). Of the 35 articles that 
met inclusion criteria in cardiovascular disease, 19 conducted by private sector 
organizations. For the 19 analyses conducted by private sector organizations, 3 
were conducted by manufacturers, of which two were large pharmaceutical compa-
nies and 1 was a nationwide pharmacy chain. ConClusions: None of the claims 
data conducted by manufacturers were small- to mid-size companies. It is unclear 
whether this is due to the cost of data and analysis or the desire to have a seem-
ingly unbiased third-party author. Further research is needed to determine why 
small- to mid-size drug, device or diagnostic manufacturers are not engaging in 
this type of research.
PHP62
a CoMPaRaTive analysis of PRivaTe HealTH insuRanCe sysTeMs in 
uniTeD sTaTes, souTH afRiCa anD TuRkey
Seyhun O., Can H., Erdol S.
Istanbul, Turkey
objeCtives: This poster presents a comparative analysis of the private health care 
insurance systems (PHI) in Turkey, United States and South Africa. Methods: OECD 
publications, Turkish Private Health Insurance Association, World Bank Reports, 
Publications of Turkish Social Security Institution (SSI) and official web pages of US 
and South Africa Departments of Health are examined for 2001-2011. Results: In 
comparison to Turkey; United States and South Africa have similar characteristics 
in terms of PHI dependence prevailing with a higher coverage. Due to lower PHI level 
in Turkey, Out of Pocket (OOP) payments constitute a significantly higher amount. 
In Turkey, PHI coverage has almost tripled over the last 10 years, but still accounts 
only for 3.40 % of the total population. The trend towards strengthening the PHI is 
basically due to the promotion of PHI solutions such as supplementary coverage 
